Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

615
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
615
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

510
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
510
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

306
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
306
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

264
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
264
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

405
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

236
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Weight-Related Self-Esteem, Group Behavioral Therapy, and Weight Loss.

Obesity (Silver Spring, Md.)·2026
Same author

Relation between Time from Onset to Randomization and Benefit Magnitude in Recent Clinical Trials of Thrombectomy for Patients with Large Ischemic Cores.

Annals of Indian Academy of Neurology·2026
Same author

Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients.

Current oncology (Toronto, Ont.)·2026
Same author

Optimizing rare neurological disease trials: Bayesian frameworks and hierarchical models for improved efficiency in clinical trial design.

Journal of biopharmaceutical statistics·2026
Same author

Dietary Supplements in the Perinatal Period.

Obstetrics and gynecology·2026
Same author

Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis.

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: Mar 7, 2026

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

11.7K

Estimating Baseline Cutoffs for DHA Dosage in Preterm Birth Prevention: A Bayesian Personalized Change-Point

Jianzheng Wu1, Danielle N Christifano2, Susan E Carlson2

  • 1Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.

Journal of Applied Statistics
|March 6, 2026
PubMed
Summary

Personalized docosahexaenoic acid (DHA) supplementation can reduce early preterm birth (ePTB) risk. A novel Bayesian model optimizes DHA doses based on individual baseline DHA levels for improved treatment strategies.

Keywords:
Clinical trial designPersonalized medicineSubgroup analysis

More Related Videos

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
09:06

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

12.7K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

704

Related Experiment Videos

Last Updated: Mar 7, 2026

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

11.7K
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
09:06

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

12.7K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

704

Area of Science:

  • Obstetrics and Gynecology
  • Nutritional Science
  • Biostatistics

Background:

  • Preterm birth (PTB) is a major cause of infant mortality, with early preterm birth (ePTB) posing the greatest risk.
  • Docosahexaenoic acid (DHA) supplementation shows potential in reducing PTB, but effectiveness varies with baseline DHA levels.
  • Current high-dose DHA strategies may not be cost-effective for all, necessitating personalized approaches.

Purpose of the Study:

  • To develop and validate a novel Bayesian personalized change-point model for optimizing DHA supplementation strategies.
  • To identify optimal baseline DHA thresholds and distributions for personalized ePTB prevention.
  • To improve secondary analysis and clinical trial design by accounting for baseline DHA heterogeneity.

Main Methods:

  • Developed a Bayesian personalized change-point model integrating dynamic linear and normal mixture models.
  • Estimated optimal DHA baseline thresholds and their distributions.
  • Applied the model to real-world data and simulated trials.

Main Results:

  • The model effectively adjusts for baseline DHA heterogeneity in secondary analyses.
  • Demonstrated improved clinical trial design through personalized DHA supplementation strategies.
  • Identified potential for optimizing DHA doses based on individual patient profiles.

Conclusions:

  • A personalized Bayesian approach can optimize DHA supplementation for ePTB prevention based on individual baseline DHA levels.
  • This model offers a framework for tailoring interventions in other studies with quantifiable patient heterogeneity.
  • Personalized medicine strategies, like optimized DHA dosing, are crucial for improving maternal and infant health outcomes.